ClinicalTrials.gg
RecruitingNCT07443033DUAL-HVPUpdated Oct 7, 2026

Psychosocial Factors in Dual Diagnosis in a General Hospital

An observational study in Dual Diagnosis, Substance Use Disorder and Mental Disorders, sponsored by Hospital Virgen del Puerto. Recruiting at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-07.

Sponsored by Hospital Virgen del Puerto · Observational

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.
Updated Oct 7, 2026Now RecruitingSite recruiting status changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Cross-sectional
Enrollment
125
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 26 studies in Substance-Related Disorders with a site in Spain — 6 open to participants now, 7 under way, none of them phase 3. Substance-Related Disorders · Spain.

Started
2026
with 1 other
Observational
6 of 26
2 open now
Registered
26th of 26
by date
Lead sponsor
1 of 26
Hospital Virgen del Puerto

Among the 26 studies in Substance-Related Disorders with a site in Spain, this one is one of 2 that started in 2026, is one of 6 observational ones, and was the 26th registered.

Substance-Related Disorders

2,242 studies on the registry are indexed under Substance-Related Disorders; 408 are open to participants now.

Browse Substance-Related Disorders studies →

Open to participants now

6 of the 26 studies in Substance-Related Disorders with a site in Spain are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 266 Substance-Related Disorders studies recruiting now, 130 (49%) set no upper age limit and 117 (44%) stop at 75 or younger; 55 take children under 18; 90 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Substance-Related Disorders with a site in Spain, or all of them as a file.
02

Study summary

Dual diagnosis, defined as the co-occurrence of a mental disorder and a substance use disorder, is frequently associated with increased clinical severity, functional impairment, and poorer health outcomes. Identifying psychosocial protective factors related to better clinical and functional outcomes is essential to improve patient care and treatment planning.

The aim of this observational, cross-sectional, single-center study is to analyze psychosocial protective factors and their association with clinical-functional outcomes in hospitalized patients with dual diagnosis. The study will be conducted in a general hospital setting and will include adult inpatients diagnosed with dual diagnosis according to clinical criteria.

Sociodemographic, clinical, and psychosocial variables will be collected using standardized assessment tools and clinical records. The results of this study are expected to contribute to a better understanding of psychosocial factors associated with clinical severity and functional outcomes in patients with dual diagnosis, supporting more comprehensive and patient-centered care approaches.

Read the detailed description

Dual diagnosis, characterized by the coexistence of a mental disorder and a substance use disorder, represents a major clinical challenge in mental health services. Patients with dual diagnosis frequently present greater clinical complexity, higher rates of hospitalization, functional impairment, and difficulties in treatment adherence. Beyond clinical variables, psychosocial factors may play a relevant role as protective elements influencing clinical and functional outcomes.

This study is designed as an observational, cross-sectional, single-center study conducted in a general hospital. The study population will consist of adult patients hospitalized with a clinical diagnosis of dual diagnosis. Participants will be recruited during their hospital admission according to predefined inclusion and exclusion criteria.

Data collection will include sociodemographic information, clinical variables related to psychiatric and substance use disorders, and psychosocial factors considered potentially protective. Clinical-functional outcomes will be assessed using standardized instruments and information obtained from medical records. All data will be collected as part of routine clinical assessment, without introducing any experimental intervention.

The primary objective of the study is to evaluate the association between psychosocial protective factors and clinical-functional outcomes in hospitalized patients with dual diagnosis. Secondary objectives include describing the sociodemographic and clinical characteristics of the study population and exploring the relationship between psychosocial variables and indicators of clinical severity.

This study does not involve the administration of investigational drugs or devices and does not modify standard clinical practice. The research protocol has been reviewed and approved by the corresponding Ethics Committee. The findings are expected to provide relevant information to support a biopsychosocial approach in the assessment and management of patients with dual diagnosis.

03

Conditions studied

  • Dual Diagnosis
  • Substance Use Disorder
  • Mental Disorders

Keywords

  • Addiction psychiatry
  • Mental health
  • Cross-sectional study
  • Observational study
  • Hospitalized patients
  • Functional outcomes
  • Clinical outcomes
  • Protective factors
  • Psychosocial factors
  • Dual diagnosis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult inpatients hospitalized in a general hospital with a clinical diagnosis of dual diagnosis.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults (≥18 years).
  • Hospitalized patients with a clinical diagnosis of dual diagnosis.
  • Ability to provide .

Exclusion criteria

Exclusion Criteria:

  • Severe cognitive impairment or acute clinical condition preventing assessment.
  • Refusal or inability to provide .
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Case-only
Time perspective
Cross-sectional
Enrollment
125 participants (estimated)
Patient registry
No

Groups and cohorts

  • Hospitalized Patients With Dual Diagnosis

    Adult inpatients diagnosed with dual diagnosis hospitalized in a general hospital.

06

What researchers measure

Primary outcomes

  1. Medication adherence measured by Simplified Medication Adherence Questionnaire (SMAQ)

    Medication adherence assessed using the 6-item Simplified Medication Adherence Questionnaire (SMAQ). Participants will be classified as adherent or non-adherent according to the original scoring criteria.

    Time frame: Baseline (within 72 hours of hospital admission)

Secondary outcomes

  1. Observed treatment adherence during hospitalization (clinical proxy index 0-3)

    Treatment adherence during hospital stay assessed using a structured clinical proxy index derived from medical records. The index ranges from 0 to 3 (0 = ≤33% adherence; 1 = 34-66%; 2 = 67-89%; 3 = ≥90%), based on medication compliance and participation in therapeutic activities.

    Time frame: At hospital discharge (average length of stay approximately 10-14 days)

  2. Clinical severity measured by Clinical Global Impression - Severity scale (CGI-S)

    Global clinical severity assessed by the treating psychiatrist using the 7-point Clinical Global Impression - Severity scale (1 = normal, 7 = extremely ill). Higher scores indicate greater illness severity.

    Time frame: Baseline (within 72 hours of hospital admission)

  3. Health-related quality of life measured by EuroQol-5D-5L index score

    Health-related quality of life assessed using the EQ-5D-5L descriptive system. The utility index score (range depends on national value set; typically \<0 to 1, where 1 indicates full health) will be calculated according to the Spanish value set.

    Time frame: Baseline (within 72 hours of hospital admission)

  4. Self-rated health status measured by EQ-5D Visual Analog Scale (VAS)

    Self-reported health status measured on a 0-100 visual analog scale, where 0 represents the worst imaginable health state and 100 the best imaginable health state.

    Time frame: Baseline (within 72 hours of hospital admission)

  5. Suicidal ideation measured by Columbia-Suicide Severity Rating Scale (C-SSRS)

    Presence of suicidal ideation assessed using the Columbia-Suicide Severity Rating Scale (C-SSRS). Participants will be categorized as having any suicidal ideation (yes/no) during the assessment.

    Time frame: Baseline (within 72 hours of hospital admission)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Individual participant data will not be shared to protect participant confidentiality and in accordance with local ethics committee approval and institutional data protection regulations.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2026 (actual). Primary completion is estimated for Apr 2027, 13 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 18, 2026
First posted
Mar 2, 2026
StartActual
Mar 1, 2026
Primary completionEst.
Apr 30, 2027
CompletionEst.
Apr 30, 2027
Last update
Oct 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 7, 2026
Sites
Hospital Virgen del Puerto is now Recruiting
Oct 7, 2026
Show all 1 update
  1. Oct 7, 2026
    Not yet recruiting→Recruiting
    Hospital Virgen del Puerto is now Recruiting
    + 2 other changes: verification date and date precision

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07443033
Lead sponsor
Hospital Virgen del Puerto
Responsible party
Sponsor
First posted
Mar 2, 2026
Start date
Mar 1, 2026
Primary completion
Apr 30, 2027 (estimated)
Completion
Apr 30, 2027 (estimated)
Last update
Oct 7, 2026

Study contacts

Guillermo F Martínez Montás, MD
Contact
guillermof.martinez@salud-juntaex.es
+34689617510
María Josefa Lorenzo Bragado, MD
study chair · Hospital Virgen del Puerto

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion